Is Kymera Therapeutics (KYMR) Balancing Pipeline Ambition and Execution Risk After New KT-621 Milestone? [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
These developments highlight both the potential of Kymera's protein degrader platform in inflammatory and allergic diseases and the execution and funding risks that remain central to its story. Next, we'll examine how the FDA Fast Track designation for KT-621 shapes Kymera's existing investment narrative and risk-reward profile. These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs . Discover why before your portfolio feels the trade war pinch. To own Kymera, you need to believe its protein degrader platform can translate into successful immunology drugs before the current cash runway and investor patience run thin. The Fast Track news for KT-621 strengthens the near term clinical catalyst, while the CEO's preset share sales and recent rating shifts do not appear to materially alter the key risk, which remains Kymera's high cash burn and dependence on successful mid stage trial execution. Among the recent announcements,
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology ProgramsGlobeNewswire
- Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13GlobeNewswire
- Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at B. Riley.MarketBeat
- Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
KYMR
Earnings
- 11/4/25 - Miss
KYMR
Sec Filings
- 1/13/26 - Form 8-K
- 1/8/26 - Form SCHEDULE
- 1/6/26 - Form 4
- KYMR's page on the SEC website